Labgenomics Co

Labgenomics Co Cash Flow per Share

The Operating Cash Flow per Share of Labgenomics Co (084650.KQ) as of Oct 27, 2026 is -3,364.25 KRW. In the previous year, Operating Cash Flow per Share was -1,431.64 KRW — a change of 134.99% (lower).

Cash Flow per Share

-3,364.25KRW

YoY

134.99%

Last updated:

Operating Cash Flow per Share of Labgenomics Co is 2025 -3,364.25 KRW. Operating Cash Flow per Share of Labgenomics Co was 2024 -1,431.64 KRW. It decreases by 134.99% lower compared to the previous year.

The Labgenomics Co Cash Flow per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Flow per Share
Date
Cash Flow per Share
Jan 1, 2018
66.99 KRW
Jan 1, 2019
351.24 KRW
Jan 1, 2020
5,108.88 KRW
Jan 1, 2021
7,201.07 KRW
Jan 1, 2022
7,697.57 KRW
Jan 1, 2023
266.82 KRW
Jan 1, 2024
-1,431.64 KRW
Jan 1, 2025
-3,364.25 KRW
The Labgenomics Co Cash Flow per Share history
YEARCash Flow per ShareYoY
-3,364.25KRW+134.99%
-1,431.64KRW-636.55%
266.82KRW-96.53%
7,697.57KRW+6.89%
7,201.07KRW+40.95%
5,108.88KRW+1,354.53%
351.24KRW+424.33%
66.99KRW-153.98%
-124.09KRW-144.30%
280.09KRW+6.97%
261.83KRW-24.47%
346.66KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Labgenomics Co Stock analysis

What does Labgenomics Co do? LabGenomics Co., Ltd. generates revenue through the provision of in vitro diagnostic (IVD) products and services. The company offers general diagnostic check services, molecular diagnostic check services, and research and development services, alongside IVD products such as DNA chips and PCR kits. Its diagnostic services include examinations for breast cancer and colorectal cancer, while its biosensor solutions target point of care testing (POCT). Additionally, LabGenomics sells healthy food as part of its product portfolio. The primary buyers of LabGenomics' services are healthcare institutions requiring diagnostic support, including hospitals and clinics. The company's molecular diagnostic services and cancer examinations are particularly sought after by medical facilities focused on specialized testing. Healthcare providers also purchase its biosensor solutions for immediate testing at the point of care. LabGenomics' product segments include IVD services, IVD products like DNA chips and PCR kits, cancer examination services, and healthy food. The company's molecular diagnostic services and cancer testing are key revenue drivers, while its biosensor for POCT and healthy food offerings serve complementary market segments. Labgenomics Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Labgenomics Co stock

Operating Cash Flow per Share of Labgenomics Co is -3,364.25 KRW in 2025.

Operating Cash Flow per Share of Labgenomics Co changed from -1,431.64 KRW to -3,364.25 KRW, representing a 134.99% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow per Share Labgenomics Co since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow per share measures the operating cash generated per outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Labgenomics Co

All Key Metrics — Labgenomics Co